The Gaithersburg, Md-based drugmaker will use the funding to speed the production of 100 million doses of its vaccine by the beginning of 2021. Novavax has never brought f a product to market, but the candidate employs the same technology as its other experimental vaccines that have gone through late-stage testing.
Results from the vaccine’s May safety trials in Australia are expected to be available in July, and Novavax plans to begin phase 3 efficacy testing during this fall.
“Adding Novavax’s candidate to Operation Warp Speed’s diverse portfolio of vaccines increases the odds that we will have a safe, effective vaccine as soon as the end of this year,” HHS Secretary Alex Azar said in a July 7 news release.
More articles on pharmacy:
Drug lobby sues Minnesota over insulin-pricing law
Regeneron begins late-stage testing of COVID-19 antibody treatment
Early use of hydroxychloroquine reduced COVID-19 deaths, study says